Kirkland has advised the underwriters in the US$368 million IPO and listing of JHBP (CY) Holdings (HKSE: 6998), a holding company for Genor Biopharma, a commercial-ready biopharmaceutical company that focuses on developing and commercializing oncology and autoimmune drugs, on the Hong Kong Stock Exchange on October 7, 2020.
The underwriters included Goldman Sachs, J.P. Morgan Securities and Jefferies Hong Kong as joint sponsors, joint global coordinators, joint bookrunners and joint lead managers; CMB International Capital, China Renaissance Securities, Haitong International Securities and Macquarie Capital as joint bookrunners and joint lead managers; and Futu Securities International and US Tiger Securities as joint lead managers.
Read the prospectus from Genor Biopharma
The Kirkland team was led by capital markets partner Li-Chien Wong with support from capital markets partners Yazhe Liu and Ben James.
